Work

Using delafloxacin, a 4th generation fluoroquinolone, in combination with nebulised tobramycin to eradicate Pseudomonas aeruginosa in cystic fibrosis

Year: 2025

Type: article

Abstract: Prompt eradication of Pseudomonas aeruginosa following isolation in sputum samples is a fundamental part of therapy in people with cystic fibrosis in order to prevent chronic infection. Whilst multiple eradication regimens exist, none have been proven to be more efficacious than any other. Eradication treatment is effective but not always successful. Ciprofloxacin has been the preferred choice of oral antimicrobial of choice in these eradication regimens due to it’s superior in-vitro activity against Pseudomonas aeruginosa compared to other fluoroquinolones. Delafloxacin, a fourth-generation fluoroquinolone, has been shown to have superior activity against Pseudomonas aeruginosa compared to ciprofloxacin in-vitro. We show herein, what we believe is the first documented successful eradication of Pseudomonas aeruginosa in a person with CF following a new isolation of the pathogen using oral delafloxacin in combination with nebulised tobramycin, instead of ciprofloxacin after the failure of first line treatment and the emergence of ciprofloxacin-resistance on antimicrobial sensitivity testing.

Source: Respiratory Medicine Case Reports

DOI: 10.1016/j.rmcr.2025.102267

Authors: Michael Kevin Dooney, Tarek Saba, Natasha Pickering, Mohamed Etumi

Institutions: Blackpool Victoria Hospital, Blackpool Teaching Hospitals NHS Foundation Trust

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,200